42393-65-7Relevant articles and documents
DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND 5-LIPOXYGENASE
-
Paragraph 107-108; 260, (2021/10/30)
The invention pertains to a novel structure (I) that provides an activity as a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and 5-lipoxygenase (5-LOX). The invention pertains to multiple derivatives of the new class of dual inhibitors, their application in medicine, pharmaceutical compositions comprising them as well as to methods for synthesizing the new compounds.
Transition-Metal-Free Three-Component Synthesis of Tertiary Aryl Amines from Nitro Compounds, Boronic Acids, and Trialkyl Phosphites
Roscales, Silvia,Csáky, Aurelio G.
supporting information, p. 111 - 117 (2019/11/16)
The synthesis of aromatic amines is of continuous interest in chemistry. An exceptionally versatile three-component reaction that directly transforms inexpensive nitro compounds, boronic acids, and trialkyl phosphites into tertiary aromatic amines has been realized. The reaction tolerates alkyl and aryl substituents on the nitro and boronic acid moieties, as well as functionalized phosphites. No transition-metal catalysis is required. The method is orthogonal to other classical metal-catalyzed syntheses since it tolerates the presence of halogens, and also permits the synthesis of functionalized compounds such as α-amino ester derivatives. (Figure presented.).
Hybrid Cholecystokinin-A Antagonists Based on Molecular Modelling of Lorglumide and L-364,718
Bent, Arie van der,Blommaert, Armand G. S.,Melman, Caroline T. M.,IJzerman, Adriaan P.,Wijngaarden, Ineke van,Soudijn, Willem
, p. 1042 - 1049 (2007/10/02)
A series of novel nonpeptide cholecystokinin-A (CCK-A) antagonists have been synthesized.Designed on the basis of the structural homology between lorgumide and L-364,718, as investigated with molecular modeling, these compounds constitute a link between the N-acylglutamic acid and 3-amino-5-phenyl-1,4-benzodiazepin-2-one derived antagonists.The prepared compounds were tested in vitro as antagonists of the binding of -(+/-)-L-364,718 and -CCK-8(S) to rat pancreas and guinea pig brain membranes, respectively.All compounds proved to be selective for the(peripheral) CCK-A receptor, the most potent analogue, 6, having a Ki value of 90 nM.The structure-activity profile of the series of hybrid compounds relates closest to that of the N-acylglutamic acid derived antagonists.